Exclusive content page featuring webinars and workshops on Safe and Sustainable by Design (SSbD), organized as part of INTEGRANO’s SSbD Hub. Registration is required to access recordings and materials from leading experts and EU projects.

Training session on harmonised QA/QC implementation in the PARC project, focusing on consistent approaches to sampling, validation, reporting, and data comparability across diverse chemical monitoring studies.

This presentation explores the production and use of certified reference materials for human biomonitoring, highlighting practical aspects of method validation, sample stability, and traceability in support of EU chemical risk assessment efforts.

This presentation focuses on the basic principles of matrix and biomarker selection in human biomonitoring, guiding participants from the identification of exposure biomarkers to their application in population studies. 

This presentation focuses on the core objectives of the HBM4EU project, providing a comprehensive overview of how each objective aligns with the project's work package structure. It highlights the strategic organisation of HBM4EU's activities and illustrates how the objectives collectively support the development of a coherent and policy-relevant human biomonitoring framework across Europe.

This presentation focuses on the role of human biomonitoring (HBM) in enhancing chemical risk assessment and supporting evidence-based policymaking. It highlights the need for reliable data on human exposure to chemicals across the EU, including variations over time, geography, and population sub-groups. The presentation also explores how HBM can inform policy by providing tools to interpret exposure data, assess health impacts, and monitor patterns and trends in chemical exposure across Europe.

This presentation focuses on exhaled breath condensate (EBC) as a biological matrix for chromium biomonitoring, explaining its production, potential applications, and the procedures for sample collection. It outlines the method developed by the Health & Safety Laboratory in the UK for chromium speciation in EBC, supported by findings from a feasibility study. 

This presentation focuses on the molecular pathways involved in the development of asbestos-related diseases, emphasising the roles of oxidative stress, DNA repair, and xenobiotic metabolism. It explores how both germline mutations and single-nucleotide polymorphisms (SNPs) within these pathways influence individual susceptibility. By understanding these mechanisms, researchers can identify clinically relevant biomarkers that support early diagnosis and risk assessment.

This presentation focuses on the fundamental terminology and principles of sampling, providing a clear overview of key concepts essential for designing and conducting human biomonitoring studies. It includes a brief introduction to the sample selection strategy developed for HBM4EU alignment studies.

This presentation provides a brief overview of key human biomonitoring (HBM) initiatives worldwide, offering insight into their scope and objectives. It includes a short introduction to the HBM4EU project, highlighting its role in coordinating efforts across Europe to advance the use of HBM in environmental health research and policymaking.

This presentation focuses on the use of blood and urine as primary biological media in HBM, outlining key characteristics of selected biomarkers in each matrix. It provides practical guidance on sample collection methods, highlighting potential pitfalls and necessary contingencies. Strategies for aliquoting and storage are discussed in detail, emphasising the importance of maintaining homogeneity in urine samples and the role of fractionation in sample pretreatment. Considerations for storage conditions, including cooling, freezing, and the use of preservatives, are also addressed to ensure sample integrity.

This presentation focuses on the concept and principles of Human Biomonitoring, specifically the classification and application of biomarkers, distinguishing between those used for exposure assessment, susceptibility evaluation, and research purposes. Highlights how the selection of specific biomarkers can provide insights into bioavailability and bioactivation over time, making them valuable tools for assessing aggregate exposure in diverse populations.

Focuses on the health risks associated with asbestos exposure, emphasizing its link to a range of diseases including asbestosis, pleural conditions, and multiple forms of cancer. Highlights malignant mesothelioma as a particularly aggressive cancer of the pleura and peritoneum, primarily caused by asbestos exposure. Discusses current challenges in diagnosing mesothelioma and the ongoing investigation into potential serum biomarkers, such as Soluble Mesothelin Related Protein (SMRP), Fibulin-3, and Survivin, for improving early detection and monitoring treatment response.